FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Study Summary

This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 in combination with trastuzumab or cetuximab; each objective will be assessed with or without paclitaxel chemotherapy.

Conditions

Non-Small Cell Lung Cancer Colorectal Cancer Breast Cancer Ovarian Cancer Endometrial Carcinoma Head and Neck Squamous Cell Carcinoma

Interventions / Drugs

FT836 Paclitaxel Cetuximab Trastuzumab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment113 participants

Primary Completion—

Lead SponsorFate Therapeutics

Data Retrieved2026-04-11 04:13:54.903251+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.